Q4 2023 Earnings Summary
- International Expansion Driving Growth: IRTC expects significant contributions to growth from international markets in 2024 and beyond, including entry into Japan (the second-largest cardiac monitoring market) in early 2025, along with expansion into Switzerland, Netherlands, Spain, and Austria. The company believes international revenues will be accretive to gross margins due to favorable reimbursement rates (e.g., Switzerland approved pricing at over CHF1,000 per test).
- Strong Recovery and Maintained Guidance Despite Temporary Headwinds: Despite weather-related impacts causing a $1 million to $2 million effect in January 2024, IRTC is maintaining its full-year revenue guidance of $575 million to $585 million, showing confidence in strong performance and recovery, with February registrations rebounding nicely.
- Significant Growth Opportunities in Primary Care Channel and IDNs: IRTC is experiencing strong momentum in the primary care channel, which now accounts for approximately 21% of registrations, and sees this as a significant opportunity to expand the total addressable market. Additionally, the company has a robust pipeline with Integrated Delivery Networks (IDNs), with some of the strongest growth coming from new networks opened in early 2024.
- Gross margin pressure due to investments and transition: iRhythm experienced lower-than-expected gross margins in the fourth quarter of 2023, primarily due to the faster-than-anticipated transition to Zio monitor and significant investments in building out the Center of Excellence in San Francisco, including hiring over 100 people in Q4 [7][14]. These pressures may continue in the near term, potentially impacting profitability.
- Reliance on successful international expansion amid potential delays: The company's growth projections rely on international markets, particularly Japan, where the launch is expected in early 2025 [8][9]. However, regulatory approvals and reimbursement negotiations may cause delays, and management anticipates a modest initial ramp in Japan. This could result in slower-than-expected international revenue contributions.
- Flat average selling prices (ASP) amidst reimbursement pressures: iRhythm expects flat ASPs in 2024, despite a 3% to 4% decrease in the CMS national rate effective January 1 [14]. The company plans to offset pricing pressures through operational efficiencies, but there is a risk that these measures may not fully compensate for reduced reimbursement rates, potentially impacting revenue growth.
-
Gross Margin Outlook
Q: How will gross margins progress, considering international expansion and investments?
A: Management expects gross margins to improve over time, reaching the low to mid-70% range outlined in their long-range plan. Despite short-term pressures from transitioning to Zio monitor and investments in the San Francisco Center of Excellence, international markets like Switzerland and Japan are anticipated to be accretive to gross margins. Switzerland approved reimbursement at over $1,000 per test , and Japan's pricing is expected to be attractive based on reference pricing models. These factors, along with automation and moving Zio MCT onto the monitor platform, are expected to enhance margins over time. -
FDA 510(k) Submissions
Q: What's the status of the FDA 510(k) submissions and their impact?
A: Both 510(k) submissions are filed with the FDA, focusing on prior letter-to-file matters and design enhancements for patient notification. Management expects formal approval around mid-year after a six-month process. The FDA has created a new category code for ambulatory cardiac monitoring, and iRhythm's Zio AT is the first product in this new category, demonstrating good progress with the FDA. This doesn't change how they sell the product but resolves regulatory issues. -
Primary Care Channel Growth
Q: How is the growth in the primary care channel affecting the business?
A: The primary care channel accounted for 21% of registrations last year and continues to grow. Integration with large health systems is expanding the total addressable market. With 15 million patients visiting primary care physicians (PCPs) for palpitations, there's significant potential beyond the current 6 million ACM tests per year. Management views this as a major tailwind and aims to accelerate TAM expansion through further integration within PCP networks. -
Competition and Market Share
Q: How is competition affecting market share, especially in primary care?
A: Despite holding 70% market share in long-term cardiac monitoring, iRhythm believes it gained additional share in 2023. Their unique approach in primary care, focusing on long-term cardiac monitoring rather than leading with MCT, positions them advantageously. Competitors are less active in primary care, allowing iRhythm to capitalize on this opportunity and potentially disrupt and expand the market beyond the historical 3-4% growth rate. -
Guidance and Weather Impact
Q: Is the Q1 weather-related revenue impact expected to be recaptured?
A: The company experienced a $1-2 million revenue impact in January due to weather but saw strong recovery in February. Management views this as a timing issue and expects to recapture these sales in later periods. They see no need to adjust full-year guidance, especially given the Q4 beat. -
Sleep Pilot Program
Q: What are the plans for the sleep pilot program and potential impact?
A: iRhythm is launching a sleep pilot within the next 30 to 60 days to address the fragmented sleep diagnosis space. Leveraging relationships with cardiologists and primary care physicians, they aim to simplify home sleep testing—a market estimated to be over $1 billion. With 50-80% of AFib patients having sleep apnea, the company sees significant opportunity to disrupt the market and create a new revenue stream. -
Operating Expenses and Margin Leverage
Q: What's driving operating expense leverage and growth expectations?
A: Adjusted operating expenses are expected to grow around 15%, excluding one-time items from 2023. There is 250 basis points of operating expense leverage in the guidance, primarily from benefits realized by the Global Business Services Center in Manila. This center is contributing to margin improvement despite ongoing investments in the company. -
Japan Launch and International Growth
Q: How will the Japan launch and international markets contribute to growth?
A: Regulatory approval in Japan is expected in the back half of the year, with commercial launch planned for early 2025. International markets are anticipated to contribute an additional point of growth in 2024, mainly from the U.K. business. Expansion plans include Switzerland, Netherlands, Spain, and Austria. Management is excited about these tailwinds, expecting international to be a significant growth contributor in both 2024 and 2025. -
Gross Margin Cadence and Automation
Q: How will gross margins improve with the monitor transition and automation?
A: Gross margins are expected to be around 66% in the first two quarters. With automation for Zio monitor coming online in the second half and 80% of volume on Zio monitor, margins are projected to improve to 68-69%, reaching 70% or higher by year-end—the highest in company history. Investments in hiring and automation are expected to yield significant payback relatively quickly. -
San Francisco IDTF Impact on ASP
Q: How will the San Francisco IDTF affect volumes and ASPs?
A: The company exited Q4 with over 50% of volumes processed through the San Francisco IDTF and expects this to grow as new hires become efficient. Despite pressures from CMS rate updates and pricing movements, optimization and utilization of the IDTF are expected to offset these factors, resulting in flat ASPs year-over-year for 2024. This serves as a tailwind heading into 2024.